Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Formaat: Artigo
Taal:Russo
Gepubliceerd in: ABV-press 2014-11-01
Reeks:Onkourologiâ
Onderwerpen:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Online toegang:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items